|Table of Contents|

The efficacy and prognosis analysis of recombinant human endostatin combined with ocitinib in the treatment of advanced non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 10
Page:
1814-1819
Research Field:
Publishing date:

Info

Title:
The efficacy and prognosis analysis of recombinant human endostatin combined with ocitinib in the treatment of advanced non-small cell lung cancer
Author(s):
YU Jinping; SUN Dongmei; LIU Haixia
Tangshan Workers' Hospital,Hebei Tangshan 063000,China.
Keywords:
recombinant human endostatin; ocitinib; advanced non-small cell lung cancer; curative effect; prognosis
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.10.009
Abstract:
Objective:To analyze the effect of recombinant human endostatin combined with ocitinib on the efficacy and prognosis of patients with advanced non-small cell lung cancer (NSCLC).Methods:A total of 92 patients with advanced NSCLC treated in hospital from June 2020 to February 2022 were selected and divided into control group and study group with 46 cases in each group by random number table method.The control group received ocitinib treatment,and the study group received recombinant human endostatin treatment based on the control group.21 days was 1 cycle,and 2 groups were treated for 3 cycles to evaluate the effect.The clinical efficacy,health status,quality of life,tumor markers,tumor-related protein factors and adverse reactions of the two groups were compared.The progression-free survival (PFS) of the two groups was recorded during 1-year follow-up.Results:The objective remission rate of the study group (50.00%) was higher than that of the control group (26.09%) (P＜0.05).The disease control rate of the study group (76.09%) was higher than that of the control group (54.35%) (P＜0.05).After 3 cycles of treatment,Karnofsky(KPS) scores and functional assessment of cancer therapy-lung (FACT-L) scores were increased in 2 groups,and higher in the study group (P＜0.05).After 3 cycles of treatment,serum cytokeratin 19 fragment (CYFRA21-1),squamous cell carcinoma antigen (SCC) and carbohydrate antigen 50 (CA50) levels in 2 groups were decreased (P＜0.05),and those in the study group were lower (P＜0.05).After 3 cycles of treatment,the relative expression of phosphatase tensin homolog (PTEN) was increased in 2 groups (P＜0.05),and higher in study group (P＜0.05).After 3 cycles of treatment,the relative expression of MUC1 was decreased in both groups (P＜0.05),and was lower in the study group (P＜0.05).There was no difference in the total incidence of grade Ⅰ to Ⅳ adverse reactions such as digestive tract reaction,thrombocytopenia,liver and kidney function injury and neutropenia between 2 groups (P＞0.05).The follow-up rate was 97.83%.The median PFS of the study group was 8.97 (95%CI:6.13~11.35) months and that of the control group was 6.53 (95%CI:3.85~9.61) months.The PFS curve of the study group was better than that of the control group (P＜0.05).Conclusion:Recombinant human endostatin combined with ocitinib is effective in the treatment of advanced NSCLC patients,which can reduce the level of tumor markers,improve the quality of life of patients,regulate the expression of tumor-related protein factors,and is safe and reliable,and can prolong the PFS of patients.

References:

［1］MITHOOWANI H,FEBBRARO M.Non-small-cell lung cancer in 2022:a review for general practitioners in oncology［J］.Curr Oncol,2022,29(3):1828-1839.
［2］ETTINGER DS,WOOD DE,AISNERD L,et al.Non-small cell lung cancer,version 3.2022,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2022,20(5):497-530.
［3］DANTOING E,PITON N,SALAUN M,et al.Anti-PD1/PD-L1 immunotherapy for non-small cell lung cancer with actionable oncogenic driver mutations［J］.Int J Mol Sci,2021,22(12):6288.
［4］HARATAKE N,SETO T.NTRK fusion-positive non-small-cell lung cancer:the diagnosis and targeted therapy［J］.Clin Lung Cancer,2021,22(1):1-5.
［5］康朔,贾海红,刘国强.奥希替尼一线治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌的成本-效用分析［J］.中国药房,2021,32(12):1492-1496. KANG S,JIA HH,LIU GQ.Cost-effectiveness analysis of ohitinib in first-line treatment of EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer ［J］.Chinese Pharmacy,2021,32(12):1492-1496.
［6］余嗣崇,王荣荣,许新举,等.回生口服液、重组人血管内皮抑制素联合GP方案对晚期非小细胞肺癌患者的临床疗效［J］.中成药,2021,43(7):1971-1973. YU SC,WANG RR,XU XJ,et al.Clinical efficacy of Huisheng oral liquid and recombinant human endostatin combined with GP regimen in patients with advanced non-small cell lung cancer ［J］.Chinese Patent Medicine,2021,43(7):1971-1973.
［7］中华医学会,中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2018版)［J］.中华肿瘤杂志,2018,40(12):935-964. Chinese Medical Association,Chinese Medical Association Oncology Branch,Chinese Medical Association Journal.Guidelines for clinical diagnosis and treatment of lung cancer of Chinese Medical Association (2018 edition)［J］.Chinese Journal of Cancer,2018,40(12):935-964.
［8］DAOUD A,KHALAF M,NASSAR M.Limitations of the karnofsky performance status scale in kidney transplant recipients［J］.Ann Med,2022,54(1):1328-1329.
［9］SCHWARTZ LH,SSYOUR L,LITIERE S,et al.RECIST 1.1-Standardisation and disease-specific adaptations:Perspectives from the RECIST working group［J］.Eur J Cancer,2016,62(3):138-145.
［10］游捷,施志明,张娴静.两种国际肺癌患者生活质量量表EORTC QLQ-LC43与FACT-L的比较［J］.中国癌症杂志,2009,19(5):364-370. YOU J,SHI ZM,ZHANG XJ.Comparison of two international quality of life scales EORTC QLQ-LC43 and FACT-L for patients with lung cancer ［J］.Chinese Journal of Cancer,2009,19(5):364-370.
［11］FREITES-MARTINEZ A,SANTANA N,ARIAS-SANTIAGO S,et al.Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies［J］.Actas Dermosifiliogr (Engl Ed),2021,112(1):90-92.
［12］WU J,LIN Z.Non-small cell lung cancer targeted therapy:drugs and mechanisms of drug resistance［J］.Int J Mol Sci,2022,23(23):15056.
［13］THEELEN W,CHEN D,VERMA V,et al.Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer:a pooled analysis of two randomised trials［J］.Lancet Respir Med,2021,9(5):467-475.
［14］KENMOTSU H,SUGAWARA S,WATANABE Y,et al.Adjuvant atezolizumab in Japanese patients with resected stage Ib-IIIa non-small cell lung cancer (IMpower010)［J］.Cancer Sci,2022,113(12):4327-4338.
［15］HIGGINS KA,PURI S,GRAY JE.Systemic and radiation therapy approaches for locally advanced non-small-cell lung cancer［J］.J Clin Oncol,2022,40(6):576-585.
［16］曹霖,生高凡,江诗琴,等.基于转录组学探讨铁死亡相关基因在奥希替尼获得性耐药NSCLC细胞中的表达及意义［J］.中国药理学通报,2022,38(4):569-576. CAO L,SHENG GF,JIANG SQ,et al.Expression and significance of iron death related genes in acquired ocitinib resistant NSCLC cells based on transcriptomics ［J］.Chinese Journal of Pharmacology,2022,38(4):569-576.
［17］陈羽中,许潇月,武渊,等.重组人血管内皮抑制素持续静脉泵注联合含铂两药化疗治疗不同病理类型非小细胞肺癌的疗效分析［J］.临床肿瘤学杂志,2021,26(8):746-749. CHEN YZ,XU XY,WU Y,et al.Effect of continuous intravenous infusion of recombinant human endostatin combined with platinum-containing two-drug chemotherapy on different pathological types of non-small cell lung cancer ［J］.Journal of Clinical Oncology,2021,26(8):746-749.
［18］乔宏伟，陈丽霞.埃克替尼与重组人血管内皮抑素持续泵入联用治疗EGFR突变阳性非小细胞肺癌的临床研究［J］.现代肿瘤医学，2019，27（03）:407-410. QIAO HW,CHEN LX.Clinical research on treatment of EGFR mutation-positive non-small cell lung cancer with combination between icotinib hydrochloride and recombinant human endostatin continuously pumped［J］.Modern Oncology，2019，27（03）:407-410.
［19］ZHU J,CHEN G,NIU K,et al.Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer［J］.Future Oncol,2022,18(9):1077-1087.
［20］潘守杰,杨静,马瑞.补肺消痿汤联合阿帕替尼治疗晚期肺癌的临床疗效及对CEA、SCC及CA125的影响［J］.中华中医药学刊,2021,39(7):180-183. PAN SJ,YANG J,MA R.Clinical efficacy of Bufei Xiaowei Decoction combined with Apatinib in the treatment of advanced lung cancer and its influence on CEA,SCC and CA125［J］.Chinese Journal of Traditional Chinese Medicine,2021,39(7):180-183.
［21］LI T,XIE Q,FANG YY,et al.Prognostic value of CYFRA 21-1 and Ki67 in advanced NSCLC patients with wild-type EGFR［J］.BMC Cancer,2023,23(1):295.
［22］HE Y,JIANG S,MAO C,et al.The deubiquitinase USP10 restores PTEN activity and inhibits non-small cell lung cancer cell proliferation［J］.J Biol Chem,2021,297(3):101088.
［23］FUSHIMI A,MORIMOTO Y,ISHIKAWA S,et al.Dependence on the MUC1-C oncoprotein in classic,variant,and non-neuroendocrine small cell lung cancer［J］.Mol Cancer Res,2022,20(9):1379-1390.
［24］FENG L,WANG Z,JING L,et al.Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer:a meta-analysis［J］.World J Surg Oncol,2021,19(1):64.
［25］任炳楠,薛朝军,李宵,等.4种治疗晚期非小细胞肺癌的抗血管生成药物Mini卫生技术评估［J］.中国新药杂志,2021,30(21):2009-2016. REN BN,XUE CJ,LI X,et al.Evaluation of four anti-angiogenic drugs Mini for the treatment of advanced non-small cell lung cancer ［J］.Chinese Journal of New Medicine,2021,30(21):2009-2016.
［26］周传江,马传胜,寿永翔.重组人血管内皮抑制素联合安罗替尼二线治疗非小细胞肺癌的临床效果［J］.中国肿瘤外科杂志,2021,13(5):509-512. ZHOU CJ,MA CS,SHOU YX.Clinical effect of recombinant human endostatin combined with anlotinib in the treatment of non-small cell lung cancer ［J］.Chinese Journal of Surgical Oncology,2021,13(5):509-512.

Memo

Memo:
河北省卫生健康委医学科学研究课题计划(编号：20181275)
Last Update: 1900-01-01